Project Grant R01HL174911
Award Date
8/6/24
Completion Date
5/31/28
Dollars Obligated
$2.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
The federal Project Grant award of $620,371, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the voltage-sensing domain (VSD) dynamics of cardiac ion channels from the CNBD family, which play a pivotal role in regulating the electrical properties of the heart. The overarching objective is to leverage advanced biophysical techniques, including patch-clamp fluorometry, transition...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Johns Hopkins University provides $1,402,988.66 in funding from September 1, 2024 to July 31, 2028. The project aims to investigate the role of protein kinase G (PKG) and the ubiquitin ligase CHIP in enhancing the degradation of mutant transthyretin to attenuate cardiac amyloidosis. Key objectives include: Testing if PKG stimulation or expression of a CHIP...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
The Ohio State University received a $157,500 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program to define the role of the KCNN1 potassium channel in atrial arrhythmias, specifically atrial fibrillation. The research aims to establish the therapeutic potential of KCNN1 as an atrial-specific antiarrhythmic target. The one-year project will utilize genetically-modified mouse models to explore how KCNN1 channel function in...
This Project Grant award of $678,803 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at The Ohio State University to investigate the role of the mitochondrial deubiquitinase USP30 in regulating cell metabolism, microRNA biogenesis, and microvascular inflammation. The overarching goal is to determine if inhibiting USP30 could be a potential therapeutic strategy for treating acute inflammatory diseases like acute respiratory...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $741,112 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Ohio State University to conduct research on the impact of the adaptive immune system on cardiac electrophysiology. The 4-year project aims to delineate the pathophysiological role of ischemic heart failure (IHF)-activated CD4+ T-cells on cardiac dysfunction, determine electrophysiological changes in cardiomyocytes resulting from IHF T-cells, and...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...